Ad Header



The Pulse of the Pharmaceutical Industry

Gilead to launch generic hepatitis drugs

Written by: | | Dated: Monday, September 24th, 2018


Gilead to launch generic versions of its hepatitis drugs


(Reuters) – Gilead Sciences Inc said on Monday it plans to launch generic versions of its hepatitis C drugs in the United States, at a time when regulators are looking to lower healthcare costs.

The drugmaker’s generic version of drugs such as Harvoni and Epclusa, which raked in combined sales of $831 million in the quarter ended June 30, will be launched via a newly created subsidiary Asegua Therapeutics LLC.

Gilead’s decision comes more than a month after the U.S. Food and Drug Administration approved Teva Pharmaceutical Industries Ltd’s copycat version of Mylan NV’s life-saving allergy injection, EpiPen.


Reuters source:

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom